Patients	O
were	O
randomized	O
1:1	O
to	O
either	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
or	O
VMP	O
treatment	O
groups	O
.	O

Patients	O
were	O
randomized	O
1:1	O
to	O
either	O
D	O
-	O
VMP	O
or	O
[P1]	O
VMP	O
treatment	O
groups	O
[P2]	O
.	O

The	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
in	O
[P1]	O
East	O
Asian	O
patients	O
[P2]	O
was	O
higher	O
for	O
D	O
-	O
VMP	O
(	O
94	O
%	O
)	O
versus	O
VMP	O
(	O
80	O
%	O
)	O
,	O
which	O
consisted	O
of	O
higher	O
rates	O
of	O
complete	O
response	O
(	O
CR	O
)	O
or	O
better	O
(	O
49	O
%	O
vs	O
21	O
%	O
)	O
and	O
very	O
good	O
partial	O
response	O
(	O
VGPR	O
)	O
or	O
better	O
(	O
81	O
%	O
vs	O
52	O
%	O
;	O

The	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
in	O
East	O
Asian	O
patients	O
was	O
higher	O
for	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
(	O
94	O
%	O
)	O
versus	O
VMP	O
(	O
80	O
%	O
)	O
,	O
which	O
consisted	O
of	O
higher	O
rates	O
of	O
complete	O
response	O
(	O
CR	O
)	O
or	O
better	O
(	O
49	O
%	O
vs	O
21	O
%	O
)	O
and	O
very	O
good	O
partial	O
response	O
(	O
VGPR	O
)	O
or	O
better	O
(	O
81	O
%	O
vs	O
52	O
%	O
;	O

The	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
in	O
East	O
Asian	O
patients	O
was	O
higher	O
for	O
D	O
-	O
VMP	O
(	O
94	O
%	O
)	O
versus	O
[P1]	O
VMP	O
[P2]	O
(	O
80	O
%	O
)	O
,	O
which	O
consisted	O
of	O
higher	O
rates	O
of	O
complete	O
response	O
(	O
CR	O
)	O
or	O
better	O
(	O
49	O
%	O
vs	O
21	O
%	O
)	O
and	O
very	O
good	O
partial	O
response	O
(	O
VGPR	O
)	O
or	O
better	O
(	O
81	O
%	O
vs	O
52	O
%	O
;	O

ORR	O
,	O
≥	O
CR	O
,	O
and	O
≥	O
VGPR	O
among	O
[P1]	O
East	O
Asian	O
patients	O
[P2]	O
treated	O
with	O
D	O
-	O
VMP	O
were	O
also	O
comparable	O
to	O
the	O
global	O
ITT	O
population	O
receiving	O
D	O
-	O
VMP	O
(	O
91	O
%	O
,	O
43	O
%	O
,	O
and	O
71	O
%	O
,	O
respectively	O
)	O
[	O
15	O
]	O
.	O

ORR	O
,	O
≥	O
CR	O
,	O
and	O
≥	O
VGPR	O
among	O
East	O
Asian	O
patients	O
treated	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
were	O
also	O
comparable	O
to	O
the	O
global	O
ITT	O
population	O
receiving	O
D	O
-	O
VMP	O
(	O
91	O
%	O
,	O
43	O
%	O
,	O
and	O
71	O
%	O
,	O
respectively	O
)	O
[	O
15	O
]	O
.	O

ORR	O
,	O
≥	O
CR	O
,	O
and	O
≥	O
VGPR	O
among	O
East	O
Asian	O
patients	O
treated	O
with	O
D	O
-	O
VMP	O
were	O
also	O
comparable	O
to	O
the	O
[P1]	O
global	O
ITT	O
population	O
[P2]	O
receiving	O
D	O
-	O
VMP	O
(	O
91	O
%	O
,	O
43	O
%	O
,	O
and	O
71	O
%	O
,	O
respectively	O
)	O
[	O
15	O
]	O
.	O

ORR	O
,	O
≥	O
CR	O
,	O
and	O
≥	O
VGPR	O
among	O
East	O
Asian	O
patients	O
treated	O
with	O
D	O
-	O
VMP	O
were	O
also	O
comparable	O
to	O
the	O
global	O
ITT	O
population	O
receiving	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
(	O
91	O
%	O
,	O
43	O
%	O
,	O
and	O
71	O
%	O
,	O
respectively	O
)	O
[	O
15	O
]	O
.	O

ORR	O
for	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
versus	O
VMP	O
was	O
96	O
%	O
versus	O
92	O
%	O
in	O
Japanese	O
patients	O
and	O
91	O
%	O
versus	O
61	O
%	O
in	O
Korean	O
patients	O
,	O
respectively	O
(	O
Table	O
2	O
)	O
.	O

ORR	O
for	O
D	O
-	O
VMP	O
versus	O
[P1]	O
VMP	O
[P2]	O
was	O
96	O
%	O
versus	O
92	O
%	O
in	O
Japanese	O
patients	O
and	O
91	O
%	O
versus	O
61	O
%	O
in	O
Korean	O
patients	O
,	O
respectively	O
(	O
Table	O
2	O
)	O
.	O

ORR	O
for	O
D	O
-	O
VMP	O
versus	O
VMP	O
was	O
96	O
%	O
versus	O
92	O
%	O
in	O
[P1]	O
Japanese	O
patients	O
[P2]	O
and	O
91	O
%	O
versus	O
61	O
%	O
in	O
Korean	O
patients	O
,	O
respectively	O
(	O
Table	O
2	O
)	O
.	O

ORR	O
for	O
D	O
-	O
VMP	O
versus	O
VMP	O
was	O
96	O
%	O
versus	O
92	O
%	O
in	O
Japanese	O
patients	O
and	O
91	O
%	O
versus	O
61	O
%	O
in	O
[P1]	O
Korean	O
patients	O
[P2]	O
,	O
respectively	O
(	O
Table	O
2	O
)	O
.	O

[P1]	O
Korean	O
patients	O
[P2]	O
also	O
achieved	O
both	O
higher	O
CR	O
or	O
better	O
(	O
44	O
%	O
vs	O
17	O
%	O
)	O
and	O
VGPR	O
or	O
better	O
(	O
83	O
%	O
vs	O
39	O
%	O
)	O
rates	O
with	O
D	O
-	O
VMP	O
compared	O
with	O
VMP	O
.	O

Korean	O
patients	O
also	O
achieved	O
both	O
higher	O
CR	O
or	O
better	O
(	O
44	O
%	O
vs	O
17	O
%	O
)	O
and	O
VGPR	O
or	O
better	O
(	O
83	O
%	O
vs	O
39	O
%	O
)	O
rates	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
compared	O
with	O
VMP	O
.	O

Korean	O
patients	O
also	O
achieved	O
both	O
higher	O
CR	O
or	O
better	O
(	O
44	O
%	O
vs	O
17	O
%	O
)	O
and	O
VGPR	O
or	O
better	O
(	O
83	O
%	O
vs	O
39	O
%	O
)	O
rates	O
with	O
D	O
-	O
VMP	O
compared	O
with	O
[P1]	O
VMP	O
[P2]	O
.	O

In	O
[P1]	O
East	O
Asian	O
patients	O
[P2]	O
in	O
the	O
D	O
-	O
VMP	O
arm	O
versus	O
the	O
VMP	O
arm	O
,	O
median	O
(	O
range	O
)	O
time	O
to	O
best	O
response	O
was	O
5.3	O
(	O
0.7	O
-	O
15.7	O
)	O
versus	O
3.5	O
(	O
0.8	O
-	O
14.4	O
)	O
months	O
,	O
and	O
median	O
duration	O
of	O
response	O
was	O
not	O
estimable	O
(	O
NE	O
)	O
versus	O
19.9	O
(	O
95	O
%	O
CI	O
,	O
13.9	O
-	O
19.9	O
)	O
months	O
.	O

In	O
East	O
Asian	O
patients	O
in	O
the	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
arm	O
versus	O
the	O
VMP	O
arm	O
,	O
median	O
(	O
range	O
)	O
time	O
to	O
best	O
response	O
was	O
5.3	O
(	O
0.7	O
-	O
15.7	O
)	O
versus	O
3.5	O
(	O
0.8	O
-	O
14.4	O
)	O
months	O
,	O
and	O
median	O
duration	O
of	O
response	O
was	O
not	O
estimable	O
(	O
NE	O
)	O
versus	O
19.9	O
(	O
95	O
%	O
CI	O
,	O
13.9	O
-	O
19.9	O
)	O
months	O
.	O

In	O
East	O
Asian	O
patients	O
in	O
the	O
D	O
-	O
VMP	O
arm	O
versus	O
the	O
[P1]	O
VMP	O
[P2]	O
arm	O
,	O
median	O
(	O
range	O
)	O
time	O
to	O
best	O
response	O
was	O
5.3	O
(	O
0.7	O
-	O
15.7	O
)	O
versus	O
3.5	O
(	O
0.8	O
-	O
14.4	O
)	O
months	O
,	O
and	O
median	O
duration	O
of	O
response	O
was	O
not	O
estimable	O
(	O
NE	O
)	O
versus	O
19.9	O
(	O
95	O
%	O
CI	O
,	O
13.9	O
-	O
19.9	O
)	O
months	O
.	O

This	O
is	O
similar	O
to	O
the	O
[P1]	O
global	O
ITT	O
population	O
[P2]	O
that	O
had	O
a	O
median	O
time	O
to	O
best	O
response	O
of	O
4.9	O
months	O
and	O
4.1	O
months	O
with	O
D	O
-	O
VMP	O
and	O
VMP	O
,	O
respectively	O
,	O
and	O
a	O
median	O
duration	O
of	O
response	O
that	O
was	O
not	O
reached	O
with	O
D	O
-	O
VMP	O
versus	O
21.3	O
(	O
95	O
%	O
CI	O
,	O
18.4-NE	O
)	O
months	O
with	O
VMP	O
[	O
15	O
]	O
.	O

This	O
is	O
similar	O
to	O
the	O
global	O
ITT	O
population	O
that	O
had	O
a	O
median	O
time	O
to	O
best	O
response	O
of	O
4.9	O
months	O
and	O
4.1	O
months	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
and	O
VMP	O
,	O
respectively	O
,	O
and	O
a	O
median	O
duration	O
of	O
response	O
that	O
was	O
not	O
reached	O
with	O
D	O
-	O
VMP	O
versus	O
21.3	O
(	O
95	O
%	O
CI	O
,	O
18.4-NE	O
)	O
months	O
with	O
VMP	O
[	O
15	O
]	O
.	O

This	O
is	O
similar	O
to	O
the	O
global	O
ITT	O
population	O
that	O
had	O
a	O
median	O
time	O
to	O
best	O
response	O
of	O
4.9	O
months	O
and	O
4.1	O
months	O
with	O
D	O
-	O
VMP	O
and	O
[P1]	O
VMP	O
[P2]	O
,	O
respectively	O
,	O
and	O
a	O
median	O
duration	O
of	O
response	O
that	O
was	O
not	O
reached	O
with	O
D	O
-	O
VMP	O
versus	O
21.3	O
(	O
95	O
%	O
CI	O
,	O
18.4-NE	O
)	O
months	O
with	O
VMP	O
[	O
15	O
]	O
.	O

Among	O
the	O
subgroups	O
,	O
the	O
median	O
(	O
range	O
)	O
time	O
to	O
best	O
response	O
for	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
versus	O
VMP	O
was	O
8.1	O
(	O
0.8	O
-	O
15.7	O
)	O
months	O
versus	O
3.5	O
(	O
0.8	O
-	O
14.4	O
)	O
months	O
in	O
Japanese	O
patients	O
and	O
4.8	O
(	O
0.7	O
-	O
14.4	O
)	O
months	O
versus	O
3.6	O
(	O
1.4	O
-	O
13.0	O
)	O
months	O
in	O
Korean	O
patients	O
.	O

Among	O
the	O
subgroups	O
,	O
the	O
median	O
(	O
range	O
)	O
time	O
to	O
best	O
response	O
for	O
D	O
-	O
VMP	O
versus	O
[P1]	O
VMP	O
[P2]	O
was	O
8.1	O
(	O
0.8	O
-	O
15.7	O
)	O
months	O
versus	O
3.5	O
(	O
0.8	O
-	O
14.4	O
)	O
months	O
in	O
Japanese	O
patients	O
and	O
4.8	O
(	O
0.7	O
-	O
14.4	O
)	O
months	O
versus	O
3.6	O
(	O
1.4	O
-	O
13.0	O
)	O
months	O
in	O
Korean	O
patients	O
.	O

Among	O
the	O
subgroups	O
,	O
the	O
median	O
(	O
range	O
)	O
time	O
to	O
best	O
response	O
for	O
D	O
-	O
VMP	O
versus	O
VMP	O
was	O
8.1	O
(	O
0.8	O
-	O
15.7	O
)	O
months	O
versus	O
3.5	O
(	O
0.8	O
-	O
14.4	O
)	O
months	O
in	O
[P1]	O
Japanese	O
patients	O
[P2]	O
and	O
4.8	O
(	O
0.7	O
-	O
14.4	O
)	O
months	O
versus	O
3.6	O
(	O
1.4	O
-	O
13.0	O
)	O
months	O
in	O
Korean	O
patients	O
.	O

Among	O
the	O
subgroups	O
,	O
the	O
median	O
(	O
range	O
)	O
time	O
to	O
best	O
response	O
for	O
D	O
-	O
VMP	O
versus	O
VMP	O
was	O
8.1	O
(	O
0.8	O
-	O
15.7	O
)	O
months	O
versus	O
3.5	O
(	O
0.8	O
-	O
14.4	O
)	O
months	O
in	O
Japanese	O
patients	O
and	O
4.8	O
(	O
0.7	O
-	O
14.4	O
)	O
months	O
versus	O
3.6	O
(	O
1.4	O
-	O
13.0	O
)	O
months	O
in	O
[P1]	O
Korean	O
patients	O
[P2]	O
.	O

The	O
median	O
duration	O
of	O
response	O
for	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
versus	O
VMP	O
was	O
NE	O
versus	O
19.9	O
(	O
95	O
%	O
CI	O
,	O
14.4	O
-	O
19.9	O
)	O
months	O
in	O
Japanese	O
patients	O
and	O
NE	O
versus	O
13.9	O
(	O
95	O
%	O
CI	O
,	O
9.6-NE	O
)	O
months	O
in	O
Korean	O
patients	O
.	O

The	O
median	O
duration	O
of	O
response	O
for	O
D	O
-	O
VMP	O
versus	O
[P1]	O
VMP	O
[P2]	O
was	O
NE	O
versus	O
19.9	O
(	O
95	O
%	O
CI	O
,	O
14.4	O
-	O
19.9	O
)	O
months	O
in	O
Japanese	O
patients	O
and	O
NE	O
versus	O
13.9	O
(	O
95	O
%	O
CI	O
,	O
9.6-NE	O
)	O
months	O
in	O
Korean	O
patients	O
.	O

The	O
median	O
duration	O
of	O
response	O
for	O
D	O
-	O
VMP	O
versus	O
VMP	O
was	O
NE	O
versus	O
19.9	O
(	O
95	O
%	O
CI	O
,	O
14.4	O
-	O
19.9	O
)	O
months	O
in	O
[P1]	O
Japanese	O
patients	O
[P2]	O
and	O
NE	O
versus	O
13.9	O
(	O
95	O
%	O
CI	O
,	O
9.6-NE	O
)	O
months	O
in	O
Korean	O
patients	O
.	O

The	O
median	O
duration	O
of	O
response	O
for	O
D	O
-	O
VMP	O
versus	O
VMP	O
was	O
NE	O
versus	O
19.9	O
(	O
95	O
%	O
CI	O
,	O
14.4	O
-	O
19.9	O
)	O
months	O
in	O
Japanese	O
patients	O
and	O
NE	O
versus	O
13.9	O
(	O
95	O
%	O
CI	O
,	O
9.6-NE	O
)	O
months	O
in	O
[P1]	O
Korean	O
patients	O
[P2]	O
.	O

Consistent	O
with	O
the	O
observed	O
response	O
rates	O
and	O
with	O
the	O
global	O
ITT	O
population	O
,	O
the	O
MRD	O
-	O
negative	O
rate	O
(	O
at	O
a	O
10	O
−5	O
sensitivity	O
threshold	O
)	O
was	O
26	O
%	O
for	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
versus	O
5	O
%	O
for	O
VMP	O
among	O
all	O
of	O
the	O
East	O
Asian	O
patients	O
.	O

Consistent	O
with	O
the	O
observed	O
response	O
rates	O
and	O
with	O
the	O
global	O
ITT	O
population	O
,	O
the	O
MRD	O
-	O
negative	O
rate	O
(	O
at	O
a	O
10	O
−5	O
sensitivity	O
threshold	O
)	O
was	O
26	O
%	O
for	O
D	O
-	O
VMP	O
versus	O
5	O
%	O
for	O
[P1]	O
VMP	O
[P2]	O
among	O
all	O
of	O
the	O
East	O
Asian	O
patients	O
.	O

Consistent	O
with	O
the	O
observed	O
response	O
rates	O
and	O
with	O
the	O
global	O
ITT	O
population	O
,	O
the	O
MRD	O
-	O
negative	O
rate	O
(	O
at	O
a	O
10	O
−5	O
sensitivity	O
threshold	O
)	O
was	O
26	O
%	O
for	O
D	O
-	O
VMP	O
versus	O
5	O
%	O
for	O
VMP	O
among	O
all	O
of	O
the	O
[P1]	O
East	O
Asian	O
patients	O
[P2]	O
.	O

In	O
[P1]	O
Japanese	O
patients	O
≥	O
75	O
years	O
of	O
age	O
(	O
D	O
-	O
VMP	O
,	O
n	O
=	O
8	O
;	O
VMP	O
,	O
n	O
=	O
10	O
)	O
[P2]	O
,	O
the	O
PFS	B-arm_efficacy_metric
benefit	O
that	O
was	O
observed	O
in	O
all	O
Japanese	O
patients	O
was	O
maintained	O
in	O
these	O
patients	O
(	O
18-	O
Table	O
2	O
in	O
Online	O
Resource	O
)	O
.	O

In	O
[P1]	O
Japanese	O
patients	O
≥	O
80	O
years	O
of	O
age	O
(	O
D	O
-	O
VMP	O
,	O
n	O
=	O
6	O
;	O
VMP	O
,	O
n	O
=	O
2	O
)	O
[P2]	O
,	O
all	O
patients	O
responded	O
to	O
treatment	O
,	O
with	O
CR	O
or	O
better	O
rate	O
being	O
67	O
%	O
versus	O
0	O
%	O
,	O
respectively	O
.	O

The	O
most	O
common	O
(	O
>	O
20	O
%	O
)	O
all	O
-	O
grade	O
treatment	O
-	O
emergent	O
adverse	O
events	O
(	O
TEAEs	O
)	O
in	O
[P1]	O
East	O
Asian	O
patient	O
groups	O
[P2]	O
are	O
presented	O
in	O
Table	O
3	O
.	O

[P1]	O
East	O
Asian	O
patients	O
[P2]	O
reported	O
a	O
higher	O
incidence	O
of	O
thrombocytopenia	O
(	O
66	O
%	O
vs	O
57	O
%	O
)	O
,	O
leukopenia	O
(	O
36	O
%	O
vs	O
32	O
%	O
)	O
,	O
and	O
lymphopenia	O
(	O
32	O
%	O
vs	O
23	O
%	O
)	O
with	O
D	O
-	O
VMP	O
and	O
VMP	O
than	O
the	O
global	O
ALCYONE	O
safety	O
population	O
(	O
thrombocytopenia	O
,	O
49	O
%	O
vs	O
54	O
%	O
;	O

East	O
Asian	O
patients	O
reported	O
a	O
higher	O
incidence	O
of	O
thrombocytopenia	O
(	O
66	O
%	O
vs	O
57	O
%	O
)	O
,	O
leukopenia	O
(	O
36	O
%	O
vs	O
32	O
%	O
)	O
,	O
and	O
lymphopenia	O
(	O
32	O
%	O
vs	O
23	O
%	O
)	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
and	O
VMP	O
than	O
the	O
global	O
ALCYONE	O
safety	O
population	O
(	O
thrombocytopenia	O
,	O
49	O
%	O
vs	O
54	O
%	O
;	O

East	O
Asian	O
patients	O
reported	O
a	O
higher	O
incidence	O
of	O
thrombocytopenia	O
(	O
66	O
%	O
vs	O
57	O
%	O
)	O
,	O
leukopenia	O
(	O
36	O
%	O
vs	O
32	O
%	O
)	O
,	O
and	O
lymphopenia	O
(	O
32	O
%	O
vs	O
23	O
%	O
)	O
with	O
D	O
-	O
VMP	O
and	O
[P1]	O
VMP	O
[P2]	O
than	O
the	O
global	O
ALCYONE	O
safety	O
population	O
(	O
thrombocytopenia	O
,	O
49	O
%	O
vs	O
54	O
%	O
;	O

The	O
occurrence	O
of	O
these	O
cytopenias	O
was	O
the	O
highest	O
among	O
[P1]	O
Japanese	O
patients	O
[P2]	O
treated	O
with	O
D	O
-	O
VMP	O
(	O
thrombocytopenia	O
,	O
75	O
%	O
;	O

The	O
occurrence	O
of	O
these	O
cytopenias	O
was	O
the	O
highest	O
among	O
Japanese	O
patients	O
treated	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
(	O
thrombocytopenia	O
,	O
75	O
%	O
;	O

In	O
[P1]	O
Japanese	O
patients	O
[P2]	O
,	O
the	O
incidence	O
of	O
peripheral	O
neuropathy	O
was	O
29	O
%	O
with	O
D	O
-	O
VMP	O
versus	O
23	O
%	O
with	O
VMP	O
;	O

In	O
Japanese	O
patients	O
,	O
the	O
incidence	O
of	O
peripheral	O
neuropathy	O
was	O
29	O
%	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
versus	O
23	O
%	O
with	O
VMP	O
;	O

In	O
Japanese	O
patients	O
,	O
the	O
incidence	O
of	O
peripheral	O
neuropathy	O
was	O
29	O
%	O
with	O
D	O
-	O
VMP	O
versus	O
23	O
%	O
with	O
[P1]	O
VMP	O
[P2]	O
;	O

in	O
[P1]	O
Korean	O
patients	O
[P2]	O
,	O
the	O
incidence	O
was	O
52	O
%	O
versus	O
67	O
%	O
,	O
respectively	O
.	O

Rates	O
of	O
all	O
-	O
grade	O
infection	O
were	O
75	O
%	O
versus	O
69	O
%	O
in	O
[P1]	O
Japanese	O
patients	O
[P2]	O
and	O
87	O
%	O
versus	O
50	O
%	O
in	O
Korean	O
patients	O
;	O

Rates	O
of	O
all	O
-	O
grade	O
infection	O
were	O
75	O
%	O
versus	O
69	O
%	O
in	O
Japanese	O
patients	O
and	O
87	O
%	O
versus	O
50	O
%	O
in	O
[P1]	O
Korean	O
patients	O
[P2]	O
;	O

all	O
-	O
grade	O
pneumonia	O
rates	O
were	O
17	O
%	O
versus	O
4	O
%	O
in	O
[P1]	O
Japanese	O
patients	O
[P2]	O
and	O
17	O
%	O
versus	O
0	O
%	O
in	O
Korean	O
patients	O
,	O
consistent	O
with	O
rates	O
observed	O
in	O
the	O
global	O
safety	O
population	O
of	O
ALCYONE	O
(	O
15	O
%	O
vs	O
5	O
%	O
,	O
respectively	O
)	O
.	O

all	O
-	O
grade	O
pneumonia	O
rates	O
were	O
17	O
%	O
versus	O
4	O
%	O
in	O
Japanese	O
patients	O
and	O
17	O
%	O
versus	O
0	O
%	O
in	O
[P1]	O
Korean	O
patients	O
[P2]	O
,	O
consistent	O
with	O
rates	O
observed	O
in	O
the	O
global	O
safety	O
population	O
of	O
ALCYONE	O
(	O
15	O
%	O
vs	O
5	O
%	O
,	O
respectively	O
)	O
.	O

Similar	O
to	O
allgrade	O
TEAEs	O
,	O
the	O
incidence	O
of	O
grade	O
3/4	O
cytopenias	O
was	O
higher	O
among	O
East	O
Asian	O
patients	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
and	O
VMP	O
(	O
neutropenia	O
,	O
55	O
%	O
vs	O
52	O
%	O
;	O

Similar	O
to	O
allgrade	O
TEAEs	O
,	O
the	O
incidence	O
of	O
grade	O
3/4	O
cytopenias	O
was	O
higher	O
among	O
East	O
Asian	O
patients	O
with	O
D	O
-	O
VMP	O
and	O
[P1]	O
VMP	O
[P2]	O
(	O
neutropenia	O
,	O
55	O
%	O
vs	O
52	O
%	O
;	O

Japanese	O
patients	O
had	O
the	O
highest	O
occurrence	O
of	O
grade	O
3/4	O
cytopenias	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
and	O
VMP	O
including	O
neutropenia	O
(	O
58	O
%	O
vs	O
62	O
%	O
)	O
,	O
thrombocytopenia	O
(	O
58	O
%	O
vs	O
46	O
%	O
)	O
,	O
leukopenia	O
(	O
63	O
%	O
vs	O
42	O
%	O
)	O
,	O
and	O
lymphopenia	O
(	O
63	O
%	O
vs	O
31	O
%	O
)	O
.	O

Japanese	O
patients	O
had	O
the	O
highest	O
occurrence	O
of	O
grade	O
3/4	O
cytopenias	O
with	O
D	O
-	O
VMP	O
and	O
[P1]	O
VMP	O
[P2]	O
including	O
neutropenia	O
(	O
58	O
%	O
vs	O
62	O
%	O
)	O
,	O
thrombocytopenia	O
(	O
58	O
%	O
vs	O
46	O
%	O
)	O
,	O
leukopenia	O
(	O
63	O
%	O
vs	O
42	O
%	O
)	O
,	O
and	O
lymphopenia	O
(	O
63	O
%	O
vs	O
31	O
%	O
)	O
.	O

The	O
incidence	O
of	O
grade	O
3	O
or	O
4	O
infections	O
among	O
East	O
Asian	O
patients	O
was	O
19	O
%	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
(	O
no	O
grade	O
4	O
events	O
)	O
versus	O
16	O
%	O
with	O
VMP	O
(	O
6	O
grade	O
3	O
events	O
;	O

The	O
incidence	O
of	O
grade	O
3	O
or	O
4	O
infections	O
among	O
East	O
Asian	O
patients	O
was	O
19	O
%	O
with	O
D	O
-	O
VMP	O
(	O
no	O
grade	O
4	O
events	O
)	O
versus	O
16	O
%	O
with	O
[P1]	O
VMP	O
[P2]	O
(	O
6	O
grade	O
3	O
events	O
;	O

In	O
Japanese	O
patients	O
,	O
the	O
incidence	O
of	O
grade	O
3	O
infections	O
was	O
21	O
%	O
with	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
versus	O
12	O
%	O
with	O
VMP	O
(	O
no	O
grade	O
4	O
events	O
observed	O
in	O
either	O
arm	O
)	O
;	O

In	O
Japanese	O
patients	O
,	O
the	O
incidence	O
of	O
grade	O
3	O
infections	O
was	O
21	O
%	O
with	O
D	O
-	O
VMP	O
versus	O
12	O
%	O
with	O
[P1]	O
VMP	O
[P2]	O
(	O
no	O
grade	O
4	O
events	O
observed	O
in	O
either	O
arm	O
)	O
;	O

in	O
Korean	O
patients	O
,	O
grade	O
3	O
or	O
4	O
infections	O
were	O
reported	O
in	O
19	O
%	O
of	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
patients	O
(	O
all	O
grade	O
3	O
)	O
versus	O
16	O
%	O
of	O
VMP	O
patients	O
(	O
all	O
grade	O
3	O
except	O
for	O
1	O
patient	O
with	O
grade	O
4	O
septic	O
shock	O
)	O
.	O

in	O
Korean	O
patients	O
,	O
grade	O
3	O
or	O
4	O
infections	O
were	O
reported	O
in	O
19	O
%	O
of	O
D	O
-	O
VMP	O
patients	O
(	O
all	O
grade	O
3	O
)	O
versus	O
16	O
%	O
of	O
[P1]	O
VMP	O
[P2]	O
patients	O
(	O
all	O
grade	O
3	O
except	O
for	O
1	O
patient	O
with	O
grade	O
4	O
septic	O
shock	O
)	O
.	O

Regarding	O
discontinuations	O
due	O
to	O
TEAEs	O
,	O
these	O
occurred	O
in	O
9	O
%	O
and	O
18	O
%	O
of	O
all	O
East	O
Asian	O
patients	O
,	O
and	O
8	O
%	O
and	O
19	O
%	O
of	O
Japanese	O
patients	O
receiving	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
and	O
VMP	O
,	O
respectively	O
;	O

Regarding	O
discontinuations	O
due	O
to	O
TEAEs	O
,	O
these	O
occurred	O
in	O
9	O
%	O
and	O
18	O
%	O
of	O
all	O
East	O
Asian	O
patients	O
,	O
and	O
8	O
%	O
and	O
19	O
%	O
of	O
Japanese	O
patients	O
receiving	O
D	O
-	O
VMP	O
and	O
[P1]	O
VMP	O
[P2]	O
,	O
respectively	O
;	O

in	O
Korean	O
patients	O
,	O
they	O
occurred	O
in	O
9	O
%	O
and	O
17	O
%	O
of	O
patients	O
receiving	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
and	O
VMP	O
,	O
respectively	O
.	O

in	O
Korean	O
patients	O
,	O
they	O
occurred	O
in	O
9	O
%	O
and	O
17	O
%	O
of	O
patients	O
receiving	O
D	O
-	O
VMP	O
and	O
[P1]	O
VMP	O
[P2]	O
,	O
respectively	O
.	O

None	O
of	O
the	O
Japanese	O
patients	O
receiving	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
discontinued	O
treatment	O
due	O
to	O
pneumonia	O
or	O
any	O
other	O
infections	O
,	O
whereas	O
2	O
Japanese	O
patients	O
receiving	O
VMP	O
discontinued	O
treatment	O
due	O
to	O
infections	O
(	O
pneumonia	O
and	O
tuberculosis	O
pleurisy	O
)	O
.	O

None	O
of	O
the	O
Japanese	O
patients	O
receiving	O
D	O
-	O
VMP	O
discontinued	O
treatment	O
due	O
to	O
pneumonia	O
or	O
any	O
other	O
infections	O
,	O
whereas	O
2	O
Japanese	O
patients	O
receiving	O
[P1]	O
VMP	O
[P2]	O
discontinued	O
treatment	O
due	O
to	O
infections	O
(	O
pneumonia	O
and	O
tuberculosis	O
pleurisy	O
)	O
.	O

Among	O
Korean	O
patients	O
,	O
1	O
patient	O
discontinued	O
due	O
to	O
infection	O
each	O
in	O
the	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
(	O
pneumonia	O
)	O
and	O
VMP	O
(	O
pelvic	O
infection	O
)	O
treatment	O
groups	O
.	O

Among	O
Korean	O
patients	O
,	O
1	O
patient	O
discontinued	O
due	O
to	O
infection	O
each	O
in	O
the	O
D	O
-	O
VMP	O
(	O
pneumonia	O
)	O
and	O
[P1]	O
VMP	O
[P2]	O
(	O
pelvic	O
infection	O
)	O
treatment	O
groups	O
.	O

For	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
versus	O
VMP	O
,	O
grade	O
3	O
infections	O
occurred	O
in	O
4	O
(	O
40	O
%	O
)	O
versus	O
1	O
(	O
13	O
%	O
)	O
Japanese	O
patients	O
and	O
in	O
1	O
(	O
20	O
%	O
)	O
versus	O
1	O
(	O
33	O
%	O
)	O
Korean	O
patient	O
,	O
respectively	O
;	O

For	O
D	O
-	O
VMP	O
versus	O
[P1]	O
VMP	O
[P2]	O
,	O
grade	O
3	O
infections	O
occurred	O
in	O
4	O
(	O
40	O
%	O
)	O
versus	O
1	O
(	O
13	O
%	O
)	O
Japanese	O
patients	O
and	O
in	O
1	O
(	O
20	O
%	O
)	O
versus	O
1	O
(	O
33	O
%	O
)	O
Korean	O
patient	O
,	O
respectively	O
;	O

none	O
of	O
the	O
discontinuations	O
due	O
to	O
TEAEs	O
in	O
the	O
[P1]	O
D	O
-	O
VMP	O
arm	O
[P2]	O
for	O
Japanese	O
and	O
Korean	O
patients	O
were	O
due	O
to	O
infections	O
.	O

Grade	O
3	O
infections	O
were	O
observed	O
in	O
2	O
(	O
33	O
%	O
)	O
Japanese	O
patients	O
≥	O
80	O
years	O
of	O
age	O
receiving	O
[P1]	O
D	O
-	O
VMP	O
[P2]	O
(	O
cytomegalovirus	O
infection	O
,	O
disseminated	O
herpes	O
zoster	O
,	O
influenza	O
,	O
and	O
pneumonia	O
[	O
n	O
=	O
1	O
each	O
]	O
)	O
and	O
1	O
receiving	O
VMP	O
(	O
50	O
%	O
;	O

Grade	O
3	O
infections	O
were	O
observed	O
in	O
2	O
(	O
33	O
%	O
)	O
Japanese	O
patients	O
≥	O
80	O
years	O
of	O
age	O
receiving	O
D	O
-	O
VMP	O
(	O
cytomegalovirus	O
infection	O
,	O
disseminated	O
herpes	O
zoster	O
,	O
influenza	O
,	O
and	O
pneumonia	O
[	O
n	O
=	O
1	O
each	O
]	O
)	O
and	O
1	O
receiving	O
[P1]	O
VMP	O
[P2]	O
(	O
50	O
%	O
;	O